{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:47:25Z","timestamp":1792928845582,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12325-023-02444-x","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T05:02:39Z","timestamp":1679461359000},"page":"2355-2374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States"],"prefix":"10.1007","volume":"40","author":[{"given":"Christopher","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Deger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado","family":"Franco-Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Proskorovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"2444_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"2444_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/2278-330X.126531","volume":"3","author":"LS Raut","year":"2014","unstructured":"Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014;3:66\u201370.","journal-title":"South Asian J Cancer"},{"key":"2444_CR3","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v116\u201325.","journal-title":"Ann Oncol"},{"key":"2444_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22\u201332.","journal-title":"Blood"},{"key":"2444_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","volume":"17","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN guidelines insights: B-cell lymphomas, version 3. J Natl Compr Canc Netw. 2019;17:650\u201361.","journal-title":"J Natl Compr Canc Netw"},{"key":"2444_CR6","unstructured":"Kite Pharma. Yescarta (axicabtagene ciloleucel) suspension for intravenous infusion: U.S. prescribing information. 2022. https:\/\/www.fda.gov\/media\/108377\/download. Accessed 20 Jan 2023."},{"key":"2444_CR7","unstructured":"Novartis. Kymriah (tisagenlecleucel) suspension for intravenous infusion: U.S. prescribing information. 2020. https:\/\/www.fda.gov\/media\/107296\/download. Accessed 20 January 2023."},{"key":"2444_CR8","unstructured":"Bristol Myers Squibb. U.S. Food and Drug Administration approves Bristol Myers Squibb\u2019s Breyanzi (lisocabtagene maraleucel), a new CAR T cell therapy for adults with relapsed or refractory large B-cell lymphoma. 2021. https:\/\/news.bms.com\/news\/details\/2021\/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Breyanzi-lisocabtagene-maraleucel-a-New-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Large-B-cell-Lymphoma\/default.aspx. Accessed 18 Apr 2022."},{"key":"2444_CR9","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.3881","volume":"10","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G, Villacampa G, Martinez-Cibrian N, et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021;10:3214\u201323.","journal-title":"Cancer Med"},{"key":"2444_CR10","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1182\/bloodadvances.2020003848","volume":"5","author":"SS Neelapu","year":"2021","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021;5:4149\u201355.","journal-title":"Blood Adv"},{"key":"2444_CR11","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1007\/s12325-021-01756-0","volume":"38","author":"G Salles","year":"2021","unstructured":"Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl J. Indirect treatment comparison of liso-cel vs. salvage chemotherapy in diffuse large B-cell lymphoma: TRANSCEND vs. SCHOLAR-1. Adv Ther. 2021;38:3266\u201380.","journal-title":"Adv Ther"},{"key":"2444_CR12","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.37765\/ajmc.2021.88737","volume":"27","author":"R Borgert","year":"2021","unstructured":"Borgert R. Improving outcomes and mitigating costs associated with CAR T-cell therapy. Am J Manag Care. 2021;27:S253\u201361.","journal-title":"Am J Manag Care"},{"issue":"Suppl 1","key":"2444_CR13","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.jval.2020.04.1592","volume":"23","author":"C Balmaceda","year":"2020","unstructured":"Balmaceda C, Abbott T, Espinoza MA. PCN92 Cost-effectiveness analysis of polatuzumab in combination with rituximab and bevacizumab for the treatment of patients with relapsed\/refractory diffuse large B-cell lymphoma. Value Health. 2020;23(Suppl 1):S40.","journal-title":"Value Health"},{"issue":"Suppl 3","key":"2444_CR14","doi-asserted-by":"publisher","first-page":"S482","DOI":"10.1016\/j.jval.2019.09.433","volume":"22","author":"KA Betts","year":"2019","unstructured":"Betts KA, Thuresson PO, Du EX, et al. PCN238 Is polatuzumab vedotin plus bendamustine-rituximab cost-effective for patients in the United States with transplant-ineligible relapsed\/refractory diffuse large B-cell lymphoma? Value Health. 2019;22(Suppl 3):S482.","journal-title":"Value Health"},{"key":"2444_CR15","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH optimal use report: axicabtagene ciloleucel for diffuse large B-cell lymphoma: economic review report. 2019. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/car-t\/ct0002-axicabtagene-ciloleucel-economic-report-redacted.pdf. Accessed 18 Apr 2022."},{"key":"2444_CR16","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH optimal use report: tisagenlecleucel for diffuse large B-cell lymphoma: economic review report. 2019. https:\/\/cadth.ca\/sites\/default\/files\/pdf\/car-t\/op0538-tisagenlecleucel-economic-report-DLBCL-jan2019.pdf. Accessed 18 Apr 2022."},{"key":"2444_CR17","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/13696998.2020.1808981","volume":"23","author":"BP Cher","year":"2020","unstructured":"Cher BP, Gan KY, Aziz MIA, et al. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed\/refractory diffuse large B-cell lymphoma from Singapore\u2019s healthcare system perspective. J Med Econ. 2020;23:1321\u20139.","journal-title":"J Med Econ"},{"issue":"Suppl 2","key":"2444_CR18","doi-asserted-by":"publisher","first-page":"S687","DOI":"10.1016\/j.jval.2020.08.1720","volume":"23","author":"K Karampampa","year":"2020","unstructured":"Karampampa K, Stene E, Axelsen F, et al. PPM3 Cost-effectiveness of axicabtagene ciloleucel (axi-cel) vs standard of care for adult patients with relapsed or refractory diffuse large B-cell lymphoma in Sweden, Norway, Finland, and Denmark. Value Health. 2020;23(Suppl 2):S687.","journal-title":"Value Health"},{"key":"2444_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/13696998.2021.1901721","volume":"24","author":"R Liu","year":"2021","unstructured":"Liu R, Oluwole OO, Diakite I, Botteman MF, Snider JT, Locke FL. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021;24:458\u201368.","journal-title":"J Med Econ"},{"key":"2444_CR20","first-page":"794","volume":"4","author":"R Liu","year":"2020","unstructured":"Liu R, Snider JT, Diakite I, Tempelaar S, Botteman M. Cost effectiveness of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for adult patients with relapsed or refractory large B-cell lymphoma (RR LBCL) in the US. HemaSphere. 2020;4:794.","journal-title":"HemaSphere"},{"key":"2444_CR21","unstructured":"National Institute for Health and Care Excellence (NICE). Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies: technology appraisal guidance [TA559]. 2019. https:\/\/www.nice.org.uk\/guidance\/ta559. Accessed 18 Apr 2022."},{"key":"2444_CR22","unstructured":"National Institute for Health and Care Excellence (NICE). Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies: technology appraisal guidance [TA567]. 2019. https:\/\/www.nice.org.uk\/guidance\/ta567. Accessed 18 Apr 2022."},{"key":"2444_CR23","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","volume":"21","author":"JA Roth","year":"2018","unstructured":"Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21:1238\u201345.","journal-title":"J Med Econ"},{"key":"2444_CR24","unstructured":"Scottish Medicines Consortium. Axicabtagene ciloleucel 0.4 \u2013 2 \u00d7 108 cells dispersion for infusion dispersion for infusion (Yescarta\u00ae). SMC Advice on New Medicines 2019. https:\/\/www.scottishmedicines.org.uk\/media\/4121\/axicabtagene-ciloleucel-yescarta-final-nov2018-for-website.pdf. Accessed 18 Apr 2022."},{"key":"2444_CR25","unstructured":"Scottish Medicines Consortium. Tisagenlecleucel 1.2 \u00d7 106 to 6 \u00d7 108 cells dispersion for infusion (Kymriah\u00ae). SMC Advice on New Medicines 2019. https:\/\/www.scottishmedicines.org.uk\/media\/4132\/tisagenlecleucel-kymriah-final-jan-2019-for-website.pdf. Accessed 18 Apr 2022."},{"key":"2444_CR26","first-page":"810","volume":"4","author":"J Sierra","year":"2020","unstructured":"Sierra J, Briones J, Calleja MA, et al. Axicabtagene ciloleucel for the management of patients with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma: an economic evaluation for Spain. HemaSphere. 2020;4:810.","journal-title":"HemaSphere"},{"key":"2444_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0035","volume":"2","author":"MD Whittington","year":"2019","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma. JAMA Netw Open. 2019;2:e190035.","journal-title":"JAMA Netw Open"},{"key":"2444_CR28","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.clinthera.2021.06.011","volume":"43","author":"CZ Qi","year":"2021","unstructured":"Qi CZ, Bollu V, Yang H, Dalal A, Zhang S, Zhang J. Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States. Clin Ther. 2021;43:1300\u201319.e8.","journal-title":"Clin Ther"},{"key":"2444_CR29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices\u2013overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32:667\u201377.","journal-title":"Med Decis Making"},{"key":"2444_CR30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"2444_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093\u2013103.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"2444_CR32","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1182\/blood-2021-148948","volume":"138","author":"JS Abramson","year":"2021","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Two-year follow-up of TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL). Blood. 2021;138(Suppl 1):2840.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2444_CR33","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1182\/blood-2021-148078","volume":"138","author":"C Jacobson","year":"2021","unstructured":"Jacobson C, Locke FL, Ghobadi A, et al. Long-term (\u22654 year and \u22655 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL). Blood. 2021;138(Suppl 1):1764.","journal-title":"Blood"},{"key":"2444_CR34","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315.","journal-title":"Lancet Oncol"},{"key":"2444_CR35","unstructured":"National Institute for Health and Care Excellence (NICE). Flexible methods for survival analysis. 2020. https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/flexible-methods-survival-analysis. Accessed 18 Apr 2022."},{"key":"2444_CR36","unstructured":"Rutherford MJ, Lambert PC, Sweeting MJ, et al. NICE DSU Technical Support Document 21. Flexible methods for survival analysis. 2020. http:\/\/www.nicedsu.org.uk.  Accessed 20 Jan 2023."},{"key":"2444_CR37","first-page":"40","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson C, Locke FL, Ghobadi A, et al. Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel). Blood. 2020;136:40\u20132.","journal-title":"Blood"},{"key":"2444_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"2444_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2020-137045","volume":"136","author":"U Jaeger","year":"2020","unstructured":"Jaeger U, Bishop MR, Salles G, et al. Myc expression and tumor-infiltrating T cells are associated with response in patients with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the JULIET trial. Blood. 2020;136:48\u20139.","journal-title":"Blood"},{"key":"2444_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40164-022-00268-z","volume":"11","author":"G Cartron","year":"2022","unstructured":"Cartron G, Fox CP, Liu FF, et al. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. Exp Hematol Oncol. 2022;11:17.","journal-title":"Exp Hematol Oncol"},{"key":"2444_CR41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-021-01144-9","volume":"14","author":"DG Maloney","year":"2021","unstructured":"Maloney DG, Kuruvilla J, Liu FF, et al. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. J Hematol Oncol. 2021;14:140.","journal-title":"J Hematol Oncol"},{"key":"2444_CR42","unstructured":"National Center for Health Statistics. National vital statistics report: United States life tables, 2017. 2019. https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr68\/nvsr68_07-508.pdf. Accessed 18 Apr 2022."},{"key":"2444_CR43","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066\u201373.","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"2444_CR44","first-page":"21","volume":"10","author":"S Adkins","year":"2019","unstructured":"Adkins S. CAR T-cell therapy: adverse events and management. J Adv Pract Oncol. 2019;10(Suppl 3):21\u20138.","journal-title":"J Adv Pract Oncol"},{"key":"2444_CR45","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708\u201315.","journal-title":"Value Health"},{"key":"2444_CR46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s41669-021-00316-0","volume":"6","author":"TA Howell","year":"2022","unstructured":"Howell TA, Matza LS, Jun MP, Garcia J, Powers A, Maloney DG. Health state utilities for adverse events associated with chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Pharmacoecon Open. 2022;6:367\u201376.","journal-title":"Pharmacoecon Open"},{"key":"2444_CR47","unstructured":"Juno Therapeutics. Breyanzi (lisocabtagene maraleucel) suspension for intravenous infusion: U.S. prescribing information. 2021. https:\/\/www.fda.gov\/media\/145711\/download. Accessed 20 Jan 2023."},{"key":"2444_CR48","unstructured":"IBM. IBM Micromedex RED BOOK. 2020. https:\/\/www.ibm.com\/products\/micromedex-red-book. Accessed 18 Apr 2022."},{"key":"2444_CR49","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG\u00a0LY.12. J Clin Oncol. 2014;32:3490\u20136.","journal-title":"J Clin Oncol"},{"key":"2444_CR50","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project: weighted national estimates from HCUP National (Nationwide) Inpatient Sample (NIS), 2017; inflated to 2020. 2017. https:\/\/hcupnet.ahrq.gov\/#setup. Accessed 18 Apr 2022."},{"key":"2444_CR51","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37:2105\u201319.","journal-title":"J Clin Oncol"},{"key":"2444_CR52","unstructured":"Institute for Clinical and Economic Review. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value. 2018. https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-101744954-pdf. Accessed 18 Apr 2022."},{"key":"2444_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","volume":"21","author":"R Hettle","year":"2017","unstructured":"Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21:1\u2013204.","journal-title":"Health Technol Assess"},{"key":"2444_CR54","unstructured":"Bristol Myers Squibb. Data on file. Liso-cel CRS and neurotoxicity analysis, BLA data cut USPI AE. 2021."},{"key":"2444_CR55","unstructured":"Institute for Clinical and Economic Review. 2020\u20132023 value assessment framework. 2020. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf. Accessed 18 Apr 2022."},{"key":"2444_CR56","unstructured":"Scottish Medicines Consortium. Polatuzumab vedotin 140mg powder for concentrate for solution for infusion (Polivy\u00ae). 2020. https:\/\/www.scottishmedicines.org.uk\/media\/5360\/polatuzumab-vedotin-polivy-final-august-2020-amended-180820-for-website.pdf. Accessed 18 Apr 2022."},{"key":"2444_CR57","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295\u2013312.","journal-title":"Am J Hematol"},{"key":"2444_CR58","unstructured":"National Institute for Health and Care Excellence (NICE). Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma [ID1166]: committee papers. 2018. https:\/\/www.nice.org.uk\/guidance\/ta567\/evidence\/appraisal-consultation-committee-papers-pdf-6718510621. Accessed 18 Apr 2022."},{"key":"2444_CR59","unstructured":"National Institute for Health and Care Excellence (NICE). Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies [ID1115]: committee papers. 2018. https:\/\/www.nice.org.uk\/guidance\/ta559\/evidence\/appraisal-consultation-committee-papers-pdf-6661404973. Accessed 18 Apr 2022."},{"key":"2444_CR60","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","volume":"28","author":"PA Riedell","year":"2022","unstructured":"Riedell PA, Hwang WT, Nastoupil LJ, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2022;28:669\u201376.","journal-title":"Transplant Cell Ther"},{"key":"2444_CR61","unstructured":"Bristol Myers Squibb. Data on File. TRANSCEND. 19 June 2020 data cut-off."},{"key":"2444_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"2444_CR63","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2147\/PPA.S44947","volume":"7","author":"LS Matza","year":"2013","unstructured":"Matza LS, Cong Z, Chung K, et al. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Prefer Adherence. 2013;7:855\u201365.","journal-title":"Patient Prefer Adherence"},{"key":"2444_CR64","unstructured":"InHealth Professional Services. Physicians' fee & coding guide. Atlanta: InHealth Record Systems; 2019."},{"key":"2444_CR65","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/jama.2015.18603","volume":"315","author":"JE Bekelman","year":"2016","unstructured":"Bekelman JE, Halpern SD, Blankart CR, et al. Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. JAMA. 2016;315:272\u201383.","journal-title":"JAMA"},{"key":"2444_CR66","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26:410\u201320.","journal-title":"Med Decis Making"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02444-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02444-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02444-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T19:15:16Z","timestamp":1682450116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02444-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02444-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}